Press conference involving POSC and major company
Seite 2 von 3 Neuester Beitrag: 15.09.10 11:42 | ||||
| Eröffnet am: | 23.04.10 20:21 | von: 0815ax | Anzahl Beiträge: | 55 |
| Neuester Beitrag: | 15.09.10 11:42 | von: 0815ax | Leser gesamt: | 19.089 |
| Forum: | Hot-Stocks | Leser heute: | 4 | |
| Bewertet mit: |  | |||
| Seite: < 1 | | 3 > | ||||
Most analysts believe that yet-to-be announced partner to be Covidien (NYSE: COV), the multi-billion dollar, worldwide leader and healthcare industry distributor whose shares trade in the fifty-dollar range on a daily basis. The site which is most often credited for breaking the news about the potential marriage between the penny stock pick and the profitble big board player, has also reported on a number of initiatives which could turn out to be very profitable for the company.
POSC's perfectly timed position as the undisputed leader in Cardio PET imaging already makes the company attractive to investors, but its revolutionary Pharm-Assist® automated radiopharmaceutical distribution device seems to be what is driving most of the radio pharma industry interest to the company.
"Our machine is not only a very attractive option for patients and doctors, but also to many of the current companies and drug manufacturers who deal in the cardiac and oncology imaging space," CEO Pat Rooney said in a recent interview. "Instead of taking on the expense of opening up a brick and mortar location for $3+ million and being worried about the expensive overhead and personnel costs of selling radiopharmaceuticals, we can install this inexpensive, automated device that is compliant with all the U.S. rules and regulations for safety and exposure issues. It works well in emergency rooms, in cardiology offices, etc. There are many benefits to it, including the fact that it saves a great deal of money, gas, and time. In addition, if you're trying to get a dose and you're the 10th person in line ordering, you may not get the dose. With our system, you're guaranteed to get a dose."
The fact that the company has chosen the Nasdaq Marketsite as a lauching platform for today's annouoncements tells us that the news must be pretty significant. Otherwise, a simple press release would have been enough. It also tells us that the new conference could turn out to be a better-late-than-never coming out party for the 27 year old company.
Shifting market conditions in the lucrative Cardiac Pet Scan sector are evident and difficult to dismiss.
"The standard of care throughout history has been SPECT technology, but really it's inferior to our PET technology," explained Rooney. "The financial reimbursement for these services from places like CMS, Medicare and Medicaid have just increased PET Reimbursement and decreased SPECT reimbursement."
A worldwide shortage of Molybdenum - a necessary isotope used for SPECT imaging is also driving more customers to Positron according to the CEO. During the last three months alone, requests for proposals at Positron have increased three-fold.
In the wild-west-like world of over the counter stocks, market makers and shorts have kept POSC shares down but it may be difficult for them to continue doing so after today's news conference. That is especially true if it turns out that partnership and all it's rumored details are actually real and substantive.
http://finance.bnet.com/bnet/news/read?GUID=12940656
danke,
schokoriegel
Optionen
| Boardmail an "Schokoriegel" |
Wertpapier: Positron |
Daher, der Zusammenbruch des Kurses gerechtferertigt und absehbar, da kurzfristige Gewinne nicht zu realisieren sind/waren....
Aufgrund der wenigen vernünftigen Informationen, die dieser Presentation zu entnehmem wahren: ich bleibe LONG, mit erstem pers. Kursziel 12/2010: 1USD *
http://www.nasdaq.com/aspx/...rdiac-diagnostic-services---quick-facts
Positron Sells Its PET Scanner To Manhattan Based Gramercy Cardiac Diagnostic Services - Quick Facts
(RTTNews) - Wednesday, Positron Corp. (POSC.OB) announced the sale and installation of its PET scanner to Manhattan based, Gramercy Cardiac Diagnostic Services, owned by prominent New York City cardiologist, Dr. Peter Rentrop.
Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution.
For comments and feedback: contact editorial@rttnews.com
Read more: http://www.nasdaq.com/aspx/...ic-services---quick-facts#ixzz0n7wjqvtW
06.05.2010 21:55
Positron Showcased at NASDAQ Marketsite
Positron Corporation (OTCBB:POSC) (the "Company") a molecular imaging solutions company focused on Nuclear Cardiology, announced the highlights from the Company's presentation before NASDAQ on May 5, 2010.
The Management of Positron Corporation introduced the Company at the NASDAQ Marketsite. This forum is of great value to Positron since it provides broad exposure and access to a far reaching investment community.
The Company set out to explain the foundation of its business, the confirmation of a strategic partnership and potential revenue. Management discussed most all aspects of the Company's plans which it was at liberty to disclose. A transcript of the presentation will be filed with the Securities and Exchange Commission on a Form 8-K immediately when it becomes available in coming days.
Positron representatives did confirm an agreement with an industry leading strategic partner that will give the Company the ability to greatly expand the Company's revenue stream and our position in the molecular imaging market by offering imaging systems and radiopharmaceutical distribution. Patrick Rooney, Positron Corporation's CEO states, "We would have liked to introduce a certain synergistic business partner as was stated in the press; however it was the recommendation of both companies to not disclose further details due to a potential expansion relationship and certain strategic competitive advantages. We anticipate additional information will be disclosed in the near future."
Positron also gave guidance as to its target revenue. Based on the Company's research and unique positioning in the marketplace, Positron projects significant sales growth quarter over quarter, year over year. Positron projects that in the next 5 years the nuclear cardiology market will approach $1.5 Billion in revenue annually. The projections reflected sales from Positron's PET device and radiopharmaceutical devices and services. Positron may potentially achieve greater revenue as it expands into new markets with broader indications that we expect will be fully supported by Medicare and private payers.
About Positron: Positron founded in 1983, is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. Positron is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.
Contacts:
Positron Corporation
Patrick Rooney
(317) 576-0183
© 2010 Business Wire
Sollte dem Aktienkurs wieder Schub geben ; )
| POSC: Damned if you do and damned if you don't |
| Written by Peter DePalma |
| Friday, 14 May 2010 05:47 |
We've come back from vacation to an email box full of both love and hate mail, thus the title of today's article. Apparently, our advice to "sell" prior to the press event did not go over well with many of the longs who felt that we were sending mixed messages about the stock, but after carefully considering what many day traders do with these "forward looking" types of stock plays, our editors felt strongly that we should advise our readers despite the potential for back lash. As it turned out, things got even uglier than any of us expected when the company decided not to announce their highly anticipated partnership details to an audience of reporters in attendance at New York's Nasdaq Marketsite. Most of the reporters covering the event didn't even blink, but the tens of thousands of investors who were following the conference via webcast immediately responded by dumping their shares. What resulted was a wave of attacks and false accusations about BMR promoting and/or pumping and dumping the stock. Those who followed the advice and erred on the side of caution won while those who decided to gamble more speculatively paid a price. At the end of the day, the facts still remain: POSC is a solid company that has been around for over 27 years. The CEO may need more media relations training given his very rough delivery at the podium, but reporters at the event (none of whom even asked about the partnership details that investors were craving) seemed to take the most interest in management's announcement that POSC anticipates generating over $200 million in revenue within 18 months and over a billion in revenue within 4 to 5 years. This is a stock that many of us have jumped back in on and is still available for mere pennies per share. Even though they fully intended to when the news conference was scheduled, POSC could not announce the name of the key partnership they wanted to reveal at the press conference for a number of reasons. As we understand it, there are at least one contractual and several strategic partnerships in the works or even already in place. As many disappointed and angry investors called and cried for full disclosure under threats of lawsuits, the company followed up with a cryptic press release about the matter in the days following the conference. Although no one at the company can go on record publicly for the same reasons we mentioned, we have confirmed to the best of our abilities and based on candid interviews with multiple sources, that Positron has partnered with Covidien (NYSE:COV). In addition, our sources tell us that they are also in the process of aligning with other big board companies for some very important strategic partnerships on the pharmaceutical side of the business. Furthermore, it's worth considering that any one of these strategic partners may choose to take a position in or even outright buy the company; especially once the new network of automated imaging drug dispensing machines is set up. BMR was told that at one point, one of Positron's newest allies had apparently gone so far as to "threaten them" before deciding that joining forces might be a better way to respond to their innovative nuclear medicine's dispensing and distribution technology. The bonding experience with that company is still shaky, but much more friendly now according to those familiar with the situation and it definitely played into why the company decided against the public revelations. |
After alerting members to Positron Corporation (OTC:POSC), the stock roared from $.06 to a fifty-two week high of $.30. Shortly after that, we
INDIANAPOLIS--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC) (the “Company”) a molecular imaging solutions company focused on Nuclear Cardiology, states that over the first 4 months of 2010 that it has seen tremendous interest in its Attrius™ dedicated cardiac PET scanner. The Attrius™ was introduced in the 4th quarter of 2009 and has been met with critical acclaim throughout the molecular imaging industry.
Patrick G. Rooney, Positron Corporation’s CEO states, “The Nuclear Cardiology industry is experiencing a shift from SPECT to PET as a result of molly shortages combined with changes in reimbursement. Positron is in an ideal position to capitalize on this shift more so than any other imaging company. The Attrius™ is a state of the art, Frost & Sullivan New Product Innovation Award winning, device that was designed to be optimized for Cardiac imaging allowing physicians an easy transition to PET. Our pipeline for PET systems has had significant increases each month since we launched the Attrius™ late last year. Our current pipeline has over 55 potential and/or pending sales with the second half on the year still too follow. We have done a very good job of positioning Positron to meet this new demand. Based on the current interest we believe we will meet or exceed our projected system sales moving forward. Positron’s objective is to be the leader in cardiac PET solutions. We believe we will continue to see substantial growth from both devices and radiopharmaceuticals."
About Positron: Positron founded in 1983, is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. Positron is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.
1. Positron has seen 55 confirmed/possible orders for the PET Scanner (55 X ca. 3,5 Mio.$) in the 1st FOUR months of 2010 alone.
2. Their PET Scanner inquiries are increasing TEN-FOLD.
3. They expect even more interest than anticipated in 2010.
4. The Covidien partnership with the apparent radio-pharm units has been inked and is not even factored into these estimates.
5. Once the Covidien partnership and pipeline of products is PUBLICLY announced...the share price will skyrocket.
Was für ein Potenzial ; )
Date : 05/20/2010 @ 5:05PM
Source : Edgar (US Regulatory)
Stock : (POSC)
http://ih.advfn.com/...=nmona&article=42917128&symbol=NB^POSC
| Positron Sees Tenfold Increase in Quote Proposals |
| Written by Staff and Wire Reports | |
| Saturday, 22 May 2010 11:22 | |
Patrick G. Rooney, Positron Corporation’s CEO states, “The Nuclear Cardiology industry is experiencing a shift from SPECT to PET as a result of molly shortages combined with changes in reimbursement. Positron is in an ideal position to capitalize on this shift more so than any other imaging company. The Attrius™ is a state of the art, Frost & Sullivan New Product Innovation Award winning, device that was designed to be optimized for Cardiac imaging allowing physicians an easy transition to PET. Our pipeline for PET systems has had significant increases each month since we launched the Attrius™ late last year. Our current pipeline has over 55 potential and/or pending sales with the second half on the year still too follow. We have done a very good job of positioning Positron to meet this new demand. Based on the current interest we believe we will meet or exceed our projected system sales moving forward. Positron’s objective is to be the leader in cardiac PET solutions. We believe we will continue to see substantial growth from both devices and radiopharmaceuticals."
|
Shares of Positron Corporation (OTCBB:
http://www.finanznachrichten.de/...diac-optimized-pet-scanner-004.htm
Positron Exhibits at the Society of Nuclear Medicine Meeting to Promote Their Cardiac Optimized PET Scanner
Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, will exhibit at the upcoming Society of Nuclear Medicine Meeting (SNM) in Salt Lake City, UT June 5th-9th to promote their cardiac optimized PET scanner, the Attrius™ (www.snm.org).
The SNM Annual Meeting has been recognized by thousands of professional attendees as the premier event for educational and networking opportunities in molecular imaging and nuclear medicine. Positron will utilize the SNM annual conference as a platform to educate its attendees about the benefits of cardiac PET and promote the Attrius™.
With the continued uncertainty of the worlds Molybdenum supply and recent increase in PET reimbursement&decrease in SPECT reimbursement, cardiac PET has seen a significant rise in demand as doctors and hospitals look toward modalities that offer better medicine to their patients while decreasing operational costs. Joseph Oliverio, Chief Technology Officer states, "The demand for Cardiovascular PET imaging is rapidly increasing as it enables the physician to provide better patient care through a more accurate diagnosis, the potential to reduce unnecessary downstream procedures and limit radiation exposure." Mr. Oliverio also went on to state, "The Attrius™ has a small footprint, robust standard cardiovascular software package, competitive scan times and an affordable cost of entry making the Attrius™ the right choice for enhancing the capabilities of a Cardiovascular practices."
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317)576-0183.
Contacts:
Positron Corporation
Joseph Oliverio, (317) 576-0183
© 2010 Business Wire
http://www.finanznachrichten.de/...on-key-points-developments-004.htm
Positron Key Points & Developments
Positron Corporation (OTCBB:POSC), a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology states the Company's key points and developments.
Positron's core focus is to leverage their unique technologies and competencies to offer an industry unique total customer solution which includes low cost molecular imaging devices and service, disease specific software, radiopharmaceutical distribution delivery systems, and imaging agents for Nuclear Cardiology. Positron's strategy is to utilize all of its innovative equipment to maximize market share within the molecular imaging market.
Positron operates through two segments: Molecular Imaging Devices and Radiopharmaceutical Products.
(...weiter siehe LINK)
http://www.finanznachrichten.de/...alued-at-dollar-35-million-004.htm
Imagin Molecular Corporation Acquires an Investment Position in Positron Corporation Currently Valued at $35 Million
The Shareholders of Imagin Molecular Corporation ("IMGM") have approved, through a consent of over 51% of shareholder vote, certain transactions wherein IMGM completed the acquisition of 3,100,000 Class B Preferred Shares of Positron Corporation which shares are convertible on a 1 for 100 basis into Positron common shares. This position marked to the current market price for Positron Corporation common shares has a value of in excess of $35 million. It is IMGM's intention to hold the Positron Class B Preferred shares for investment purposes. The consideration for the exchange of the Positron investment position is the issuance of 310,000,000 common shares of IMGM to IMAGIN Diagnostic Centres, Inc. (IDC) a private Canadian company that is in the PET scanning business in Canada and a historical owner of the 3,100,000 Class B preferred block equity position. IMGM simultaneously announces its intent to build Cardiac Disease Reversal and Prevention Clinics across Canada and, after initial success, across the USA and globally. The new subsidiary will be named "Positron Cardiac CARE Clinics". These clinics will base its imaging technology on Positron's Attrius™ dedicated cardiac PET scanners.
Currently IMGM holds approximately one Positron common share equivalent for each IMGM common share outstanding. Positron preferred shares have been held by IMGM since 2005. Upon completion of the exchange of Positron preferred shares for IMGM common shares, IMGM will own the equivalent of 386,235,800 Positron common shares and upon completion of this transaction IMGM will have 405,000,000 common shares outstanding with no significant debt or preferred stock outstanding.
(...weiter siehe LINK)
http://biomedreports.com/articles/most-popular/44674-positron-seeing-substantial-accumulation-may-pierce-resistance-levels.html
| Positron seeing substantial accumulation. May pierce resistance levels. |
| Written by M.E.Garza |
| Thursday, 17 June 2010 14:32 |
The stock has been seeing quite a bit of accumulation since shares broke the $.10 support level a few days ago and Thursday, shares closed up 11.6% at $.125. We believe the stock will climb higher pending announcements and long awaited official revelation of a key relationship or two with big-cap firms in the biotech imaging space. Those relationships and developments, as they are announced, may signal what investors have been waiting for: the validation and start of next level of commercialization and deployment activities surrounding the company's Molecular Imaging Devices and Radiopharmaceutical Products. Here is a marked up technical analysis chart of the company:
|
Positron Corporation (OTCBB:POSC), a leader in molecular imaging and solutions specializing in the field of Nuclear Cardiology has just released a report over the news wires highlighting some of the company's key points and developments.
(...weiter siehe LINK)
21.06.2010 15:44
Positron Announces Sales of Attrius™ PET Scanners
Positron Corporation (OTCBB:POSC), a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology, announces the sales of four Attrius™ PET scanners to prominent cardiology practices and orders six Attrius™ PET scanners from its joint venture, Neusoft Positron Medical Systems for immediate delivery.
As a result of the Centers for Medicare&Medicaid Services (CMS) 2010 Medicare Physician Fee Schedule whereby reimbursement for cardiac PET increased and reimbursement for SPECT decreased there has been a significant increase in demand for cardiac PET imaging. When combining the economic and medical imaging advantages of cardiac PET compounded with the continued shortage of Molybdenum, the parent radioisotope used in SPECT imaging, this increase in the demand for cardiac PET is a trend that is expected to continue.
Positron's cardiac optimized dedicated PET scanner the Attrius™ is the right choice at the right time for cardiovascular practices. With recent sales, Positron has met its six month projections and predicts greater demand moving forward. Based on Positron's sales pipeline and in preparation of meeting the next six month projections, the Company has place a purchase order for six systems for their earliest delivery. Positron's organic growth targets sales of 17 PET systems for 2010, 50 PET systems for 2011 and 125 PET systems for 2012 and fully expects to meet these goals.
Patrick G. Rooney, Chief Executive Officer of Positron stated, "Positron has always been a leader in cardiac PET and we continue to make progress that further validates our position that PET is the future of nuclear cardiology. Positron is ideally positioned with the Attrius™ as the only dedicated cardiac PET offering available. This year has seen the emergence of cardiac PET and Positron. Our objective is to meet the strong demand and be the full solutions provider for cardiac PET adopters. Positron projects an increase in sales every quarter for the foreseeable future and is prepared to deliver. Positron's corporate focus is aggressive growth while staying on track to deliver positive earnings within 18 months."
(...weiter siehe LINK)
08.07.2010 18:31
Due to Demand Positron is Increasing Production of Attrius™ PET Scanners
Positron Corporation (OTCBB:POSC), a molecular imaging and solutions company specializing in Nuclear Cardiology and a leader in Cardiac PET, announces that due to a greater demand for the Attrius™ PET scanner, the Company has recently begun increasing production capacities with its joint venture, Neusoft Positron Medical Systems.
Positron's award-winning, cardiac optimized PET scanner, the Attrius™, is the only advanced, dedicated, cost-effective PET scanner in the marketplace. The introduction of the Attrius™ last year has generated excitement throughout the cardiac molecular imaging industry. Facilitated by the increase in reimbursement for cardiac PET and an industry-wide movement to better and more efficient medical imaging, Positron's Attrius™ has seen unprecedented interest and sales. As a result of the recent sales, Positron has met its six month projections and has to increase production earlier than previous estimations. Based on Positron's current sales and a more robust pipeline, the Company believes that they will surpass 2010 and 2011 targets of approximately 70 systems in the next 18 months.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317)576-0183.
Contacts:
Positron Corporation
Patrick G. Rooney, (317)576-0183
© 2010 Business Wire
http://www.finanznachrichten.de/...gmp-manufacturing-facility-004.htm
Positron Announces Opening of cGMP Manufacturing Facility
Facility to Focus on Production of Positron Emission Tomography Pharmaceuticals
Positron Corporation (OTCBB:POSC), a molecular imaging and solutions company specializing in Nuclear Cardiology and a leader in Cardiac PET, announced today the opening of a cGMP ready (current good manufacturing practices) facility in Indiana for the manufacturing of both radioactive and non-radioactive pharmaceutical products and devices.
"The opening of this facility marks a significant milestone in Positron's expansion into the consumables market that began with the acquisition of Dose Shield in 2008," stated John Zehner, COO of Positron. "Radioactive and non-radioactive pharmaceutical products are a key component of our Company's growth strategy; the opening of such a facility affords us significant advantages in every aspect of our business, which enables us to remain competitive in the future. The opening of this manufacturing facility was critical to our plan, as we are now equipped with the staff, equipment and space necessary to manufacture a variety of radioactive and non-radioactive pharmaceutical products. While the Company's plan is to focus on small batch, radioactive PET products, the facility will also be utilized to support current and future Positron equipment, as well as, expand into new markets. We are presently in discussions with several entities that can utilize our contract manufacturing services," concluded Mr. Zehner.
The Company noted the approximate 10,000 square foot facility, with room for expansion, contains ample clean room space and laboratory equipment to support the production of pharmaceutical and support products for both industrial and medical use. These products will meet or exceed Food and Drug Administration (FDA) current good manufacturing practices (cGMP's). This will allow for the production of products under 510k's, ANDA's, NDA's and IND's, as well as, certified compounding products for pharmacy use.
...(weiter siehe LINK)
© 2010 Business Wire
http://www.finanznachrichten.de/...ovative-distribution-model-004.htm
Positron Announces Strategic Alliance with Covidien; to Develop Innovative Distribution Model
Positron Corporation (OTCBB:POSC), announced it has signed an agreement with Covidien (NYSE:COV), a leading global provider of healthcare products, under which Covidien will provide technical assistance to Positron in connection with Positron's development of technology to automate the compounding of radiopharmaceuticals.
The agreement combines Covidien's expertise in radiopharmaceuticals and regulatory issues with Positron's expertise in automation and radiopharmaceuticals. Automating the distribution of radiopharmaceuticals has many benefits, ranging from worker safety to cost savings to enhanced customer service.
"Positron continues to provide unique solutions to the molecular imaging community," said John Zehner, COO of Positron. "This agreement provides Positron with various advantages and additional resources. We are very excited to collaborate with Covidien on this project."
... (weiter siehe LINK)
For the quarterly period ended | JUNE 30, 2010 |
LINK: ih.advfn.com/p.php
The numbers of shares outstanding of each of the issuer's classes of common equity, as of August 23, 2010, are as follows: 773,452,547
Common Stock: $0.01 par value; 800,000,000 shares authorized
---
Customer deposits represent amounts paid to the Company by customers for devices in advance of manufacturing completion and/or shipment of the device to the customer. Deposit amounts may vary depending on the contract. Included in customer deposits at June 30, 2010 were deposits of approximately $669,000 from a customer that had placed an order for five Nuclear Pharm-Assist™ systems. As of the date of this report, there can be no assurance that this customer will fulfill its order for these devices. Accordingly, deposits related to this customer have been reclassified from unearned revenue to customer deposits. Also included in customer deposits at June 30, 2010, are $390,000 of deposits for sales of two Attrius™ Cardiac PET systems. At June 30, 2010, the Company paid $1,149,000 in deposits for six Attrius machines for which the Company has six pending sales contracts as of August 23, 2010.
--
Business Transaction
On August 18, 2010, the Company announced a strategic alliance with Covidien a large global healthcare company for product development of its proprietary dose dispensing devise. The Company will act as an independent contractor to design and develop a new version of its proprietary automated dose dispensing equipment specifically designed for use exclusively with Covidien radiopharmaceutical products.
--
Cash and cash equivalents at June 30, 2010 were $3,411,000 compared to $165,000 at December 31, 2009. The increase in cash is due in large part to significant equity investments made during the six months ended June 30, 2010 and deposits received for Attrius systems not yet shipped.
(Quelle: ihub / investorshub.advfn.com/boards/board.aspx )
Date : 09/13/2010 @ 7:30AM
Source : GlobeNewswire Inc.
Stock : Positron Corporation (POSC)
Positron Corporation (OTCBB:POSC), a molecular imaging company specializing in Nuclear Cardiology and a leader in Cardiac PET, announced today the grand opening of its Clinical and Technical Cardiovascular PET Training Institute in Niagara Falls, NY.
The training center will educate physicians, technologists, nurses and administrators on the use and benefits of cardiac PET imaging in the daily operations of their facility. The training will be done in a partnership with the Heart Center of Niagara where Positron's medical director, Michael E. Merhige, M.D., F.A.C.C currently operates a Coronary Artery Disease Reversal and Prevention Center guided by Positron PET imaging technologies.
Positron's chief technical officer, Joe Oliverio, stated, "This center will be a critical tool in building awareness of the tangible benefits a dedicated cardiac PET scanner yields. Creating a center specifically geared towards disseminating information is critically important as we work to grow the adaptation of PET scanners into the medical imaging marketplace. As an early adaptor of cardiac PET imaging, Dr. Merhige is an ideal ambassador to the medical community; tapping into the combined decades of experience Dr. Merhige and Positron's clinical staff possess, will allow a seamless transition of users from SPECT to PET."
Dr. Michael E. Merhige said, "Cardiac PET has been around since 1995, but only until very recently has the necessary peer-reviewed literature been available to allow for its proper recognition. PET scanning for cardiac use exposes the patient to significantly reduced levels of radiation, compared to SPECT, while affording physicians a highly effective diagnostic tool. I am pleased to play a role in educating my peers on the benefits of a cardiac PET scanner."